Respiratory Distress Syndrome, NewbornNCT01959009
High Frequency Oscillatory Ventilation Combined With Intermittent Sigh Breaths: Effects on Blood Oxygenation and Stability of Oxygenation
A study testing HFOV combined with sigh breaths in people with Respiratory Distress Syndrome, Newborn and Bronchopulmonary Dysplasia, run by Copenhagen University Hospital, Rigshospitalet at 1 site in Denmark.
Trial summary
Background: Ventilator induced lung injury (VILI) remains a problem in neonatology. High frequency oscillatory ventilation (HFOV) provides effective gas exchange with minimal pressure fluctuation around a continuous distending pressure and therefore small tidal volume. Read more about this study
- Who is it for?
- Ages 24 to 44 weeks
- Conditions the study is for
- Respiratory Distress Syndrome, Newborn, Bronchopulmonary Dysplasia, Ventilator Induced Lung Injury
- What is being tested?
- HFOV combined with sigh breaths
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 16 participants
- Where
- 1 siteDenmark
- Study dates
- Aug 2014to Jun 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 24 to 44 weeks
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- Infants at 24-36 weeks corrected gestational age
- Already ventilated with high frequency ventilation
- Requiring FiO2=21%-70% to maintain adequate oxygen saturation.
- Clinical stable
- o i.e. ventilated on current settings for more than just a few hours with stable but not necessarily normalized blood gases or transcutaneous values and oxygen requirement.
- Parent(s) or guardian able and willing to provide informed consent
Who cannot join
- Major congenital cardiovascular or respiratory abnormalities.
- The attending neonatologist responsible for the baby considers one of the ventilation modes unsuitable for the infant.
- Poor skin integrity precluding use of transcutaneous monitoring.
- Lack of parental signed written informed consent.
- Parents under 18 years of age.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Does High Frequency Oscillatory Ventilation Combined With Intermittent Sigh Breaths Improve Oxygenation Compared to High Frequency Oscillatory Ventilation Without Sigh Breaths in Neonates?
Background:
Ventilator induced lung injury (VILI) remains a problem in neonatology. High frequency oscillatory ventilation (HFOV) provides effective gas exchange with minimal pressure fluctuation around a continuous distending pressure and therefore small tidal volume. Animal studies showed that recruitment and maintenance of functional residual capacity (FRC) during HFOV ("open lung concept") could reduce lung injury.
Read more
"Open lung HFOV" is achieved by delivering a moderate high mean airway pressure (MAP) using oxygenation as a guide of lung recruitment. Some neonatologists suggest combining HFOV with recurrent sigh-breaths (HFOV-sigh) delivered as modified conventional ventilator-breaths at a rate of 3/min. The clinical observation is that HFOV-sigh leads to more stable oxygenation, quicker weaning and shorter ventilation. This may be related to improved lung recruitment. This has however to our knowledge not been tested in a clinical trial using modern ventilators.
Purpose, aims:
- To compare HFOV-sigh with HFOV-only and determine if there is a difference in oxygenation expressed as a/A-ratio and/or stability of oxygenation expressed as percentage time with oxygen saturation outside the reference range.
- To provide information on feasibility and treatment effect of HFOV-sigh to assist planning larger studies. We hypothesize that oxygenation is better during HFOV-sigh.
Methods:
Infants at 24-36 weeks corrected gestational age already on HFOV are eligible. Patients will be randomly assigned to HFOV-sigh (3 breaths/min) followed by HFOV-only or vice versa for 4 alternating 1-hours periods (2-treatment, double crossover design, each patient being its own control). During HFOV-sigh set-pressure will be reduced to keep MAP constant, otherwise HFOV will remain at pretrial settings. Outcome will be calculated from normal clinical parameters including pulx-oximetry and transcutaneous monitoring of oxygen and carbon-dioxide partial pressures.
Read the detailed description
High frequency oscillatory ventilation (HFOV) has been used in neonatal respiratory care for more than three decades. HFOV provides effective gas exchange with minimal pressure fluctuation around a set mean airway pressure (MAP) functioning as a continuous distending pressure (CDP), and low tidal volume compared to conventional ventilation (CV). HFOV was therefore thought to be able to reduce the risk of bronchopulmonary dysplasia in ventilated preterm babies. However results from randomized controlled trials comparing HFOV with conventional ventilation have been conflicting and meta-analyses have not shown clear evidence that HFOV is safer or more effective than conventional ventilation neither when used as initial strategy nor as rescue strategy in preterm babies with respiratory distress syndrome (RDS). Consequently there are no absolute indications for HFOV in preterm babies and most neonatologists today use HFOV as a rescue mode when conventional ventilation is failing in the acute setting of RDS as well as in the baby with bronchopulmonary dysplasia.
Maintaining adequate functional residual capacity (FRC) together with the fraction of inspired oxygen FiO2 are the main determinants of oxygenation. The larger the FRC, the larger is the volume of available oxygen in the alveoli for gas transport. Adequate oxygen saturation (SAT) of the blood in room air or an improvement in oxygen-saturation without changing the fraction of inspired oxygen can be seen as an indirect indicator of normal or normalized FRC, and most neonatologists use oxygenation as an indirect marker for lung volume during HFOV.
The CDP or set-MAP is the main determinant of lung-aeration during HFOV. A too low MAP may cause non-homogenous aeration and atelectasis leading to atelectotrauma and redirection of airflow to more compliant alveoli leading to localized hyperinflation.
Accordingly, early animal studies showed that recruitment and maintenance of FRC during HFOV could reduce lung injury. Lung recruitment was initially achieved by superimposing conventional ventilation (CV) breaths on top of HFOV with lower MAP than used today, either as recurrent sustained inflations lasting 15-20 seconds about every 20 minute, as intermittent sigh breaths (3-5 tidal breaths pr minute) delivered as normal conventional breaths or as conventional ventilation at normal rate combined with HFOV.
Today most neonatologists perform this so-called "open lung" concept by adjusting the set-MAP using oxygenation as an indirect guide of lung recruitment. Different approaches are used explained by difficulties in direct bedside monitoring of FRC. Some initiate HFOV with MAP 2-3 cm H2O above the MAP needed during conventional ventilation subsequently adjusting MAP until the fraction of inspired O2 (FiO2) <0.25-0.6 providing no signs of over inflation of the lungs on x-ray. Others go through a more complex step-wise increase in MAP till FiO2 cannot be reduced further, and then gradually decrease MAP until FiO2 again needs to be increased to maintain a predefined SAT and then continues ventilations with a MAP set at 2 cm H2O above this point, thereby placing ventilation on the more compliant deflation limb of the pressure-volume relationship of the lung.
During HFOV, MAP may be adjusted as mentioned above. Further increase in MAP may increase FRC by increased aeration and consequently improve oxygenation. Although recent clinical trials suggest this approach is safe, it could potentially lead to generalized hyperinflation and volutrauma in addition to interfering with systemic venous return and cardiac output especially if not combined with direct monitoring of lung volume which is currently not available in routine clinical care.
Combining intermittent recruitment sigh breaths at a rate of 3-5 breaths/minute with HFOV could be an alternate way of assisting in maintaining or normalizing FRC during which MAP is only increased temporarily and intermittently. This could in theory lead to quicker weaning in MAP, less oxygen exposure and potentially reduced lung injury. A concern however could be, that the intermittent sigh breaths will lead to intermittent excessive pressures in distal airways and to excessive tidal volume and accordingly not be beneficial at all. Nevertheless the approach of combining HFOV and sigh breaths at a low rate seems to be encouraged by a number of neonatologist.
It has however to our knowledge not yet been tested in a controlled human trial.
A search on PubMed revealed no human or animal trials comparing HFOV combined with intermittent recruitment sigh-breaths at a low rate. Also no trials exploring this approach are currently registered on www.clinicaltrials.gov.
To our knowledge so far only one human trial comparing HFVO with recruitment breaths at low rate has been registered but never published (Texas Infant Star Trial).
Combining HFOV with conventional breaths has only been reported in a limited number of studies and only with focus on HFOV combined with CV at normal rate showing a possible benefit. Similar results have been reported when comparing High frequency Jet Ventilation (HFVJ) combined with CV at normal rate with HFVJ alone.
Trial rationale:
Combining intermittent recruitment sigh breaths at a low rate with HFOV could offer a further way of assisting in maintaining or normalizing FRC with only modest or no increase in MAP in alignment with the open lung concept.
A concern however could be, that the intermittent sigh breaths will lead to intermittent increased pressures in distal airways and too large tidal volume and accordingly not be beneficial at all. Despite this, the approach of combining HFOV and sigh breaths seems to be encouraged by a number of neonatologist.
It has however, to our knowledge not yet been tested in a controlled human trial. We therefore wish to conduct a controlled cross-over trial assessing the effect of HFOV combined with intermittent sigh breaths on oxygenation in ventilated neonates using oxygenation as an indirect indicator of lung recruitment.
Objective and hypothesis:
The objectives of this trial are to:
- Compare HFOV combined with intermittent recruitment sigh breaths at a rate of 3/min (HFOV-sigh) with HFOV only (HFOV-only) and examine if:
- oxygenation expressed as a/A-ratio improves with HFOV-sigh
- a/A-ratio is a measure of oxygenation and calculated as
- a/A-ratio = paO2/(0,95*FiO2- PaCO2),
- paO2 and PaCO2 are measured on arterial blood if arterial access is in situ otherwise as transcutaneous values (see further down).
- stability of oxygenation improves with HFOV-sigh
- expressed as a calculation of the percentage deviation of time spent outside the reference range for oxygen-saturation (SAT) for the given gestational age (AUC - area-under-the-curve) and comparing this with MAP and FiO2.
- Evaluate the possibility of setting up a larger randomized controlled trial We hypothesize that during HFOV-sigh the oxygenation will be improved as well at the stability of oxygenation with less time spent outside the reference range for SAT at an unchanged or lower FiO2
Trial design:
The trial is planned as a 4-period 2-treatment, double crossover clinical trial with each patient being its own control. Patients will be randomly assigned to receive HFOV-Sigh followed by HFOV-only or vice versa for four alternating 1-hours periods.
- Conditions
- Respiratory Distress Syndrome, Newborn, Bronchopulmonary Dysplasia, Ventilator Induced Lung Injury
- Being tested
- HFOV combined with sigh breaths
- Keywords
- newborn, lung disease, mechanical ventilation, lung recruitment, high frequency ventilation
- Medical subject headings
- Respiratory Distress Syndrome, Newborn, Bronchopulmonary Dysplasia, Ventilator-Induced Lung Injury, Lung Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
HFOV combined with sigh breathsOther
We plan only to investigate infants already ventilated on the HFOV-modus on high frequency oscillators, where the HFOV modus can be superimposed on conventional modes of ventilation. This gives the opportunity to combine HFOV with intermittent sigh breaths with a pre-set frequency and pre-set peak inspiratory pressure (PIP) and thus comparing HFOV combined with sigh breaths (HFOV-sigh) with conventional HFOV (HFOV-only).
All included participants will be exposed to the two different ventilator strategies tested in this trial, albeit in alternating and different order.
Each patient will serve, as it's own control. The trial will involve four alternating 1-hours periods allowing a sufficient "wash-out" period, as it has been shown that alveolar recruitment and derecruitment may take up to 25 min after changes to ventilator pressures At study start the patients will randomly be assigned to either starting with HFOV-only or HFOV-sigh
| Study group | Role | What they receive |
|---|---|---|
| HFOV-sigh at start | Experimental | Each patient will be exposed to either HFOV alone (HFOV-only) or HFOV combined with sigh breaths (HFOV-sigh), but in different order.
MAP=mean airway pressure.
DURING HFOV-SIGH:
* Frequency 3 breaths/min
* Ti = 1s
* Peak inspiratory pressure (PIP) = 30 cm H2O
For patients already on HFOV-sigh at study start:
• MAP-set will be left unchanged at pre-trial settings.
For patients on HFOV-only at study start:
• During periods with superimposed sigh breaths, MAP-set will be reduced in accordance with a calculation of MAP aiming to keep average mean airway-pressure (MAP) unchanged. (MAP=(PIP*Tinsp+PEEP*Texp)/(Tinsp+Texp)
DURING HFOV-ONLY
For patients on HFOV-sigh at study start:
• During HFOV-only, the MAP-set will be increased in accordance with a calculation of MAP, aiming to keep average mean airway-pressure (MAP) unchanged.
For patients on HFOV-only at study start:
• MAP-set will be left unchanged at pre-trial settings. Receives: Other: HFOV combined with sigh breaths |
| HFOV-only at start | Experimental | Each patient will be exposed to either HFOV alone (HFOV-only) or HFOV combined with sigh breaths (HFOV-sigh), but in different order.
MAP=mean airway pressure.
DURING HFOV-SIGH:
* Frequency 3 breaths/min
* Ti = 1s
* Peak inspiratory pressure (PIP) = 30 cm H2O
For patients already on HFOV-sigh at study start:
• MAP-set will be left unchanged at pre-trial settings.
For patients on HFOV-only at study start:
• During periods with superimposed sigh breaths, MAP-set will be reduced in accordance with a calculation of MAP aiming to keep average mean airway-pressure (MAP) unchanged. (MAP=(PIP*Tinsp+PEEP*Texp)/(Tinsp+Texp)
DURING HFOV-ONLY
For patients on HFOV-sigh at study start:
• During HFOV-only, the MAP-set will be increased in accordance with a calculation of MAP, aiming to keep average mean airway-pressure (MAP) unchanged.
For patients on HFOV-only at study start:
• MAP-set will be left unchanged at pre-trial settings. Receives: Other: HFOV combined with sigh breaths |
What is being measured
The primary outcome is the main question the study is designed to answer.
Delta-a/A-ratio
a/A-ratio calculated as a/A-ratio= TcPO2/(0,95*FiO2- TcPCO2) By delta-a/A-ratio means the difference in a/A-ratio between the two modes of ventilation, as an indirect measure of lung recruitment.
Measured: on study day
stability of oxygen saturation
The difference in area-under-the-curve for "out of range" for oxygen saturation (based on accepted general reference ranges for the given gestational age).
Measured: on study day
Secondary outcomes (4)
FiO2
Difference in fraction of inspired oxygen between the two ventilator modes
Measured: on study day
Partial pressure of CO2
Difference in transcutaneous pCO2 between the two ventilator modes
Measured: on study day
heart rate
Difference in heart rate between the two ventilator modes
Measured: on study date
Partial pressure of O2
Difference in partial pressure of oxygen measured transcutaneously between the two ventilator modes
Measured: on study date
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Oct 2013 (estimated)
- Study startAug 2014
- Primary completionJun 2022 (estimated)
- Study completionJun 2022 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Respiratory Distress Syndrome, NewbornStudies of the same condition, open and under way.
- More trials run by Copenhagen University Hospital, RigshospitaletThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Enrolment
- 16 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Copenhagen University Hospital, Rigshospitalet
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Christian Heiring, Copenhagen University Hospital, Rigshospitalet
- Investigators
- Christian Heiring, md, Principal investigator, Copenhagen University Hospital, Rigshospitalet
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01959009
- Sponsor's protocol ID
- H-2-2012-167
- Status last verified
- Oct 2020
- First submitted
- 7 Oct 2013
- Last updated
- 20 Oct 2020
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 Oct 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Does High Frequency Oscillatory Ventilation Combined With Intermittent Sigh Breaths Improve Oxygenation Compared to High Frequency Oscillatory Ventilation Without Sigh Breaths in Neonates?
- ClinicalTrials.gov ID
- NCT01959009
- Acronym / sponsor ID
- H-2-2012-167
- Conditions
- Respiratory Distress Syndrome, Newborn, Bronchopulmonary Dysplasia, Ventilator Induced Lung Injury
- Keywords
- newborn, lung disease, mechanical ventilation, lung recruitment, high frequency ventilation
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 16 participants (estimated)
- Lead sponsor
- Copenhagen University Hospital, RigshospitaletUniversity, hospital or other
- Study start
- Aug 2014
- Primary completion
- Jun 2022 (estimated)
- Study completion
- Jun 2022 (estimated)
- First posted
- 9 Oct 2013 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Background:
Ventilator induced lung injury (VILI) remains a problem in neonatology. High frequency oscillatory ventilation (HFOV) provides effective gas exchange with minimal pressure fluctuation around a continuous distending pressure and therefore small tidal volume. Animal studies showed that recruitment and maintenance of functional residual capacity (FRC) during HFOV ("open lung concept") could reduce lung injury.
"Open lung HFOV" is achieved by delivering a moderate high mean airway pressure (MAP) using oxygenation as a guide of lung recruitment. Some neonatologists suggest combining HFOV with recurrent sigh-breaths (HFOV-sigh) delivered as modified conventional ventilator-breaths at a rate of 3/min. The clinical observation is that HFOV-sigh leads to more stable oxygenation, quicker weaning and shorter ventilation. This may be related to improved lung recruitment. This has however to our knowledge not been tested in a clinical trial using modern ventilators.
Purpose, aims:
- To compare HFOV-sigh with HFOV-only and determine if there is a difference in oxygenation expressed as a/A-ratio and/or stability of oxygenation expressed as percentage time with oxygen saturation outside the reference range.
- To provide information on feasibility and treatment effect of HFOV-sigh to assist planning larger studies. We hypothesize that oxygenation is better during HFOV-sigh.
Methods:
Infants at 24-36 weeks corrected gestational age already on HFOV are eligible. Patients will be randomly assigned to HFOV-sigh (3 breaths/min) followed by HFOV-only or vice versa for 4 alternating 1-hours periods (2-treatment, double crossover design, each patient being its own control). During HFOV-sigh set-pressure will be reduced to keep MAP constant, otherwise HFOV will remain at pretrial settings. Outcome will be calculated from normal clinical parameters including pulx-oximetry and transcutaneous monitoring of oxygen and carbon-dioxide partial pressures.
Detailed description
High frequency oscillatory ventilation (HFOV) has been used in neonatal respiratory care for more than three decades. HFOV provides effective gas exchange with minimal pressure fluctuation around a set mean airway pressure (MAP) functioning as a continuous distending pressure (CDP), and low tidal volume compared to conventional ventilation (CV). HFOV was therefore thought to be able to reduce the risk of bronchopulmonary dysplasia in ventilated preterm babies. However results from randomized controlled trials comparing HFOV with conventional ventilation have been conflicting and meta-analyses have not shown clear evidence that HFOV is safer or more effective than conventional ventilation neither when used as initial strategy nor as rescue strategy in preterm babies with respiratory distress syndrome (RDS). Consequently there are no absolute indications for HFOV in preterm babies and most neonatologists today use HFOV as a rescue mode when conventional ventilation is failing in the acute setting of RDS as well as in the baby with bronchopulmonary dysplasia.
Maintaining adequate functional residual capacity (FRC) together with the fraction of inspired oxygen FiO2 are the main determinants of oxygenation. The larger the FRC, the larger is the volume of available oxygen in the alveoli for gas transport. Adequate oxygen saturation (SAT) of the blood in room air or an improvement in oxygen-saturation without changing the fraction of inspired oxygen can be seen as an indirect indicator of normal or normalized FRC, and most neonatologists use oxygenation as an indirect marker for lung volume during HFOV.
The CDP or set-MAP is the main determinant of lung-aeration during HFOV. A too low MAP may cause non-homogenous aeration and atelectasis leading to atelectotrauma and redirection of airflow to more compliant alveoli leading to localized hyperinflation.
Accordingly, early animal studies showed that recruitment and maintenance of FRC during HFOV could reduce lung injury. Lung recruitment was initially achieved by superimposing conventional ventilation (CV) breaths on top of HFOV with lower MAP than used today, either as recurrent sustained inflations lasting 15-20 seconds about every 20 minute, as intermittent sigh breaths (3-5 tidal breaths pr minute) delivered as normal conventional breaths or as conventional ventilation at normal rate combined with HFOV.
Today most neonatologists perform this so-called "open lung" concept by adjusting the set-MAP using oxygenation as an indirect guide of lung recruitment. Different approaches are used explained by difficulties in direct bedside monitoring of FRC. Some initiate HFOV with MAP 2-3 cm H2O above the MAP needed during conventional ventilation subsequently adjusting MAP until the fraction of inspired O2 (FiO2) <0.25-0.6 providing no signs of over inflation of the lungs on x-ray. Others go through a more complex step-wise increase in MAP till FiO2 cannot be reduced further, and then gradually decrease MAP until FiO2 again needs to be increased to maintain a predefined SAT and then continues ventilations with a MAP set at 2 cm H2O above this point, thereby placing ventilation on the more compliant deflation limb of the pressure-volume relationship of the lung.
During HFOV, MAP may be adjusted as mentioned above. Further increase in MAP may increase FRC by increased aeration and consequently improve oxygenation. Although recent clinical trials suggest this approach is safe, it could potentially lead to generalized hyperinflation and volutrauma in addition to interfering with systemic venous return and cardiac output especially if not combined with direct monitoring of lung volume which is currently not available in routine clinical care.
Combining intermittent recruitment sigh breaths at a rate of 3-5 breaths/minute with HFOV could be an alternate way of assisting in maintaining or normalizing FRC during which MAP is only increased temporarily and intermittently. This could in theory lead to quicker weaning in MAP, less oxygen exposure and potentially reduced lung injury. A concern however could be, that the intermittent sigh breaths will lead to intermittent excessive pressures in distal airways and to excessive tidal volume and accordingly not be beneficial at all. Nevertheless the approach of combining HFOV and sigh breaths at a low rate seems to be encouraged by a number of neonatologist.
It has however to our knowledge not yet been tested in a controlled human trial.
A search on PubMed revealed no human or animal trials comparing HFOV combined with intermittent recruitment sigh-breaths at a low rate. Also no trials exploring this approach are currently registered on www.clinicaltrials.gov.
To our knowledge so far only one human trial comparing HFVO with recruitment breaths at low rate has been registered but never published (Texas Infant Star Trial).
Combining HFOV with conventional breaths has only been reported in a limited number of studies and only with focus on HFOV combined with CV at normal rate showing a possible benefit. Similar results have been reported when comparing High frequency Jet Ventilation (HFVJ) combined with CV at normal rate with HFVJ alone.
Trial rationale:
Combining intermittent recruitment sigh breaths at a low rate with HFOV could offer a further way of assisting in maintaining or normalizing FRC with only modest or no increase in MAP in alignment with the open lung concept.
A concern however could be, that the intermittent sigh breaths will lead to intermittent increased pressures in distal airways and too large tidal volume and accordingly not be beneficial at all. Despite this, the approach of combining HFOV and sigh breaths seems to be encouraged by a number of neonatologist.
It has however, to our knowledge not yet been tested in a controlled human trial. We therefore wish to conduct a controlled cross-over trial assessing the effect of HFOV combined with intermittent sigh breaths on oxygenation in ventilated neonates using oxygenation as an indirect indicator of lung recruitment.
Objective and hypothesis:
The objectives of this trial are to:
- Compare HFOV combined with intermittent recruitment sigh breaths at a rate of 3/min (HFOV-sigh) with HFOV only (HFOV-only) and examine if:
- oxygenation expressed as a/A-ratio improves with HFOV-sigh
- a/A-ratio is a measure of oxygenation and calculated as
- a/A-ratio = paO2/(0,95*FiO2- PaCO2),
- paO2 and PaCO2 are measured on arterial blood if arterial access is in situ otherwise as transcutaneous values (see further down).
- stability of oxygenation improves with HFOV-sigh
- expressed as a calculation of the percentage deviation of time spent outside the reference range for oxygen-saturation (SAT) for the given gestational age (AUC - area-under-the-curve) and comparing this with MAP and FiO2.
- Evaluate the possibility of setting up a larger randomized controlled trial We hypothesize that during HFOV-sigh the oxygenation will be improved as well at the stability of oxygenation with less time spent outside the reference range for SAT at an unchanged or lower FiO2
Trial design:
The trial is planned as a 4-period 2-treatment, double crossover clinical trial with each patient being its own control. Patients will be randomly assigned to receive HFOV-Sigh followed by HFOV-only or vice versa for four alternating 1-hours periods.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| HFOV-sigh at start | Experimental | Other: HFOV combined with sigh breathsEach patient will be exposed to either HFOV alone (HFOV-only) or HFOV combined with sigh breaths (HFOV-sigh), but in different order. MAP=mean airway pressure. DURING HFOV-SIGH: * Frequency 3 breaths/min * Ti = 1s * Peak inspiratory pressure (PIP) = 30 cm H2O For patients already on HFOV-sigh at study start: • MAP-set will be left unchanged at pre-trial settings. For patients on HFOV-only at study start: • During periods with superimposed sigh breaths, MAP-set will be reduced in accordance with a calculation of MAP aiming to keep average mean airway-pressure (MAP) unchanged. (MAP=(PIP*Tinsp+PEEP*Texp)/(Tinsp+Texp) DURING HFOV-ONLY For patients on HFOV-sigh at study start: • During HFOV-only, the MAP-set will be increased in accordance with a calculation of MAP, aiming to keep average mean airway-pressure (MAP) unchanged. For patients on HFOV-only at study start: • MAP-set will be left unchanged at pre-trial settings. |
| HFOV-only at start | Experimental | Other: HFOV combined with sigh breathsEach patient will be exposed to either HFOV alone (HFOV-only) or HFOV combined with sigh breaths (HFOV-sigh), but in different order. MAP=mean airway pressure. DURING HFOV-SIGH: * Frequency 3 breaths/min * Ti = 1s * Peak inspiratory pressure (PIP) = 30 cm H2O For patients already on HFOV-sigh at study start: • MAP-set will be left unchanged at pre-trial settings. For patients on HFOV-only at study start: • During periods with superimposed sigh breaths, MAP-set will be reduced in accordance with a calculation of MAP aiming to keep average mean airway-pressure (MAP) unchanged. (MAP=(PIP*Tinsp+PEEP*Texp)/(Tinsp+Texp) DURING HFOV-ONLY For patients on HFOV-sigh at study start: • During HFOV-only, the MAP-set will be increased in accordance with a calculation of MAP, aiming to keep average mean airway-pressure (MAP) unchanged. For patients on HFOV-only at study start: • MAP-set will be left unchanged at pre-trial settings. |
Who may qualify
- Ages
- 24 to 44 weeks
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (6 listed)
- Infants at 24-36 weeks corrected gestational age
- Already ventilated with high frequency ventilation
- Requiring FiO2=21%-70% to maintain adequate oxygen saturation.
- Clinical stable
- o i.e. ventilated on current settings for more than just a few hours with stable but not necessarily normalized blood gases or transcutaneous values and oxygen requirement.
Key exclusion criteria (5 listed)
- Major congenital cardiovascular or respiratory abnormalities.
- The attending neonatologist responsible for the baby considers one of the ventilation modes unsuitable for the infant.
- Poor skin integrity precluding use of transcutaneous monitoring.
- Lack of parental signed written informed consent.
- Parents under 18 years of age.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| HFOV combined with sigh breathsWe plan only to investigate infants already ventilated on the HFOV-modus on high frequency oscillators, where the HFOV modus can be superimposed on conventional modes of ventilation. This gives the opportunity to combine HFOV with intermittent sigh breaths with a pre-set frequency and pre-set peak inspiratory pressure (PIP) and thus comparing HFOV combined with sigh breaths (HFOV-sigh) with conventional HFOV (HFOV-only). All included participants will be exposed to the two different ventilator strategies tested in this trial, albeit in alternating and different order. Each patient will serve, as it's own control. The trial will involve four alternating 1-hours periods allowing a sufficient "wash-out" period, as it has been shown that alveolar recruitment and derecruitment may take up to 25 min after changes to ventilator pressures At study start the patients will randomly be assigned to either starting with HFOV-only or HFOV-sigh | Other | HFOV-only at start, HFOV-sigh at start |
Primary outcome
Delta-a/A-ratio
Time frame: on study day
a/A-ratio calculated as a/A-ratio= TcPO2/(0,95*FiO2- TcPCO2) By delta-a/A-ratio means the difference in a/A-ratio between the two modes of ventilation, as an indirect measure of lung recruitment.
stability of oxygen saturation
Time frame: on study day
The difference in area-under-the-curve for "out of range" for oxygen saturation (based on accepted general reference ranges for the given gestational age).
4 secondary outcomes
FiO2
Time frame: on study day
Partial pressure of CO2
Time frame: on study day
heart rate
Time frame: on study date
Partial pressure of O2
Time frame: on study date
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Oct 2020.
Related trials for Respiratory Distress Syndrome, Newborn
Enrolling by invitation
Personalized Ventilator Settings for Patients on ECMO
Acute Respiratory Distress Syndrome (ARDS), Extracorporeal Membrane Oxygenation
Not yet recruitingObservational study
Development and Multicenter Validation of an Explainable System for Neonatal ARDS-Compatible Phenotyping
Acute Respiratory Distress Syndrome
RecruitingObservational study
Assessment of Blood Viscosity in ARDS (Acute Respiratory Distress Syndrome)
ARDS
Recruiting
Comparing Surfactant Administration Through Supraglottic Airway and Thin Catheter for Preterm Infants
Surfactant, Respiratory Distress Syndrome (Neonatal)
Recruiting
REspiratory MEchanics for Delivering Individualised Exogenous Surfactant
Respiratory Distress Syndrome in Premature Infant
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Christian Heiring, md principal investigator
Copenhagen University Hospital, Rigshospitalet
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing HFOV combined with sigh breaths in people with Respiratory Distress Syndrome, Newborn and Bronchopulmonary Dysplasia, run by Copenhagen University Hospital, Rigshospitalet at 1 site in Denmark.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 20 Oct 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Delta-a/A-ratio (time frame: on study day). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Oct 2020.